Total Voting Rights

RNS Number : 2661A

ValiRx PLC

31 July 2008

 



31 July 2008    

ValiRx plc 

Total Voting Rights

For the purposes of the transitional provisions of the Financial Services Authority's Disclosure and Transparency Rules, the total number of ordinary shares of 6p each in the capital of the Company in issue as at the date of this notice is 52,999,759 with each share carrying the right to one vote.

There are no shares held in treasury.

Therefore, the total number of voting rights in the Company is 52,999,759.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules.

Enquiries: 

ValiRx plc Dr. Satu Vainikka	Tel: [phone]
WH Ireland Limited - Nominated Adviser	Tel: [phone]
David Youngman / Adrian Kirk
College Hill	Tel: [phone]
Adrian Duffield/Justine Lamond	[e-mail]

Notes to Editors

About ValiRx - www.valirx.com

ValiRx plc (AIM:VAL, 'ValiRx') is a cancer therapeutics and diagnostics company headquartered in London, England and admitted to AIM in October 2006. The Company operates through two subsidiaries, ValiPharma (formerly trading as Cronos Therapeutics) (www.valipharma.com), a UK-based epigenetic drug discovery and development business and ValiBio SA (www.valibio.com), a Belgium-based oncology diagnostics operation.

Therapeutics - ValiPharma

ValiRx utilises a cells own inherent gene control machinery to silence genes involved in cancer cell progression, effectively 'switching off' genes involved in certain forms of cancer through its platform technology GeneICE™ (Gene Inactivation by Chromatin Engineering),. GeneICE™ works through the recruitment of silencing complexes known as Histone Deacetylase Complexes (HDACs) to target genes involved in cancer. ValiRx's lead product VAL 101 targets the anti-apoptotic gene BCL-2 which is over expressed in many cancers including in pancreatic cancer. The Company has also recently expanded its pre-clinical portfolio to include VAL 201 in prostate cancer.

Gene silencing technology platform potentially represents an innovative and ground breaking new approach to cancer treatment as it allows for the development of targeted, personalised medicine and treatment for patients. GeneICE™ is also applicable to a wide variety of other genetic disorders such as in the fields of neurology and inflammatory diseases.

Diagnostics - ValiBio

ValiRx currently has two epigenetic diagnosis products - HyperGenomics™, a method for the detection and identification of hypersensitive sites in cells and Nucleosomics™, a non-invasive (blood) test for early cancer diagnosis based on epigenetic signal changes associated with malignancy - which it licences to its subsidiary, ValiBio.

Epigenetics

Epigenetics is the study and manipulation of regulatory factors which regulate and determine gene expression.

Unlike mutations which occur in DNA, epigenetic changes are reversible. The 'epigenetic' modification of the genome may take many forms, such as addition of external chemical groups for example methylation, acetylation and ubiquitination on to histone proteins associated with DNA.

Research currently suggests the de-regulation of normal epigenetic control mechanisms is implicated in the development and progression of certain cancers. Hence, compounds which specifically target and reverse these changes are attractive and potentially powerful candidates for future therapeutic approaches to cancer.

Personalised medicine

Personalised medicine refers to tailoring treatment strategies to work differently in different individuals, dependant upon such factors such as their genetic profile, epigenetic profile, environment and the presence of other diseases in the individual.

 

END

 

 

TVREAKXEDLKPEFE